BidaskClub lowered shares of Establishment Labs (NASDAQ:ESTA) from a hold rating to a sell rating in a research note issued to investors on Tuesday, BidAskClub reports.

ESTA has been the subject of a number of other research reports. Zacks Investment Research raised shares of Establishment Labs from a sell rating to a hold rating in a research report on Monday, February 3rd. ValuEngine downgraded shares of Establishment Labs from a buy rating to a hold rating in a research report on Tuesday, February 4th. Finally, BTIG Research assumed coverage on shares of Establishment Labs in a research report on Wednesday, February 5th. They issued a buy rating and a $40.00 target price for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $31.50.

Establishment Labs stock traded down $0.14 during mid-day trading on Tuesday, reaching $24.89. The company’s stock had a trading volume of 6,693 shares, compared to its average volume of 139,063. The company has a market capitalization of $529.64 million, a price-to-earnings ratio of -11.80 and a beta of 0.58. Establishment Labs has a 12 month low of $16.55 and a 12 month high of $30.06. The business’s 50 day simple moving average is $27.26 and its 200 day simple moving average is $22.97. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.52 and a current ratio of 4.81.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). The business had revenue of $22.85 million during the quarter, compared to the consensus estimate of $20.00 million. Establishment Labs had a negative net margin of 52.76% and a negative return on equity of 75.10%. As a group, sell-side analysts expect that Establishment Labs will post -2.12 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Victory Capital Management Inc. lifted its stake in shares of Establishment Labs by 63.9% during the 4th quarter. Victory Capital Management Inc. now owns 3,493 shares of the company’s stock worth $97,000 after buying an additional 1,362 shares during the last quarter. Granite Point Capital Management L.P. bought a new position in Establishment Labs during the fourth quarter worth about $238,000. Vanguard Group Inc. bought a new position in Establishment Labs during the second quarter worth about $349,000. Millennium Management LLC increased its position in Establishment Labs by 90.7% during the third quarter. Millennium Management LLC now owns 40,184 shares of the company’s stock worth $759,000 after acquiring an additional 19,107 shares during the period. Finally, Kornitzer Capital Management Inc. KS increased its position in Establishment Labs by 148.7% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 37,300 shares of the company’s stock worth $1,032,000 after acquiring an additional 22,300 shares during the period. Institutional investors own 44.21% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.

See Also: How can investors find ex-dividend dates?

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.